計算機科學技術名家講座
（2014-3）
講座題目：Error profile analysis of Illumina sequencing data: R&D-derived business operations and beyond
主 講 人：李彤彬博士，美國AccuraScience公司總裁、首席生物信息學家
講座時間：2014年3月7日上午9:30
講座地點：前衛南校區計算機大樓A521報告廳
主辦單位：伟德国际BETVlCTOR
伟德国际BETVlCTOR計算機科學技術研究所
伟德国际BETVlCTOR軟件學院
符号計算與知識工程教育部重點實驗室
歡迎廣大師生踴躍參加！
簡介：李彤彬，1991年獲北京大學生物物理學學士學位，2000年獲威斯康星－麥德遜大學神經生物學博士學位，2001年獲休斯敦大學計算機科學碩士學位，2004年到2009年在美國明尼蘇達大學任助理教授，2009年到2013年在美國LC Sciences公司任生物信息總監，2013年起任美國AccuraScience公司總裁、首席生物信息學家。李彤彬博士在2004年明尼蘇達大學任教起以來共發表文章約40篇，帶隊開發、發表了10多個生物信息軟件和網站，獲美國國家健康研究院等聯邦和地方科研經費經費資助約180萬美元，并在多家國際學術刊物任編委。
摘要：Rapid advances in next-generation sequencing (NGS) technologies have
induced drastic changes in how biomedical research is conducted.
Currently, multiple NGS technologies are offering substantially higher
throughput in producing sequencing data at much reduced cost, when
compared to Sanger sequencing. Despite these extraordinary advantages,
current NGS technologies also possess two distinct disadvantages,
namely, short read lengths and high error rates. Consequently,
NGS-based resequencing is generally regarded as a high-throughput
variant screening procedure, rather than a reliable variant
identification routine. Focusing on data generated from Illumina - one
of the most successful NGS platforms, we closely examined the error
profiles of these data in a novel "read-centric" approach. Our
discovery prompted a fresh look at each of the two limitations
previously believed to be intrinsically associated with NGS
technologies. In this talk, I will not only describe this story as a
R&D project, but also discuss how it was extended into two lines of
business operations. Moreover, I will offer a view about the direction
the bioinformatics industry is moving towards [The presentation will
be made in Chinese].
